Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthijs J Scheltema

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
The Journal of Urology|August 10, 2022
Final Analysis of the Magnetic Resonance Imaging in Active Surveillance TrialPaul Doan, Matthijs J Scheltema, Amer Amin, et al.
The Journal of Urology|September 12, 2022
Reply by AuthorsPaul Doan, Matthijs J Scheltema, Amer Amin, et al.
BJU International|April 27, 2022
Outcomes of salvage radical prostatectomy after initial irreversible electroporation treatment for recurrent prostate cancerLuigi A M J G van Riel, Bart Geboers, Ertunc Kabaktepe, et al.
BJU International|December 10, 2022
Salvage irreversible electroporation for radio-recurrent prostate cancer - the prospective FIRE trialAlexandar Blazevski, Bart Geboers, Matthijs J Scheltema, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 4, 2022
Robot-Assisted Prostate-Specific Membrane Antigen-Radioguided Surgery in Primary Diagnosed Prostate CancerWilliam Gondoputro, Matthijs J Scheltema, Alexander Blazevski, et al.
The Journal of Urology|December 12, 2019
The Magnetic Resonance Imaging in Active Surveillance (MRIAS) Trial: Use of Baseline Multiparametric Magnetic Resonance Imaging and Saturation Biopsy to Reduce the Frequency of Surveillance Prostate BiopsiesAmer Amin, Matthijs J Scheltema, Ron Shnier, et al.
BJU International|January 21, 2020
Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancerAmer Amin, Alexandar Blazevski, James Thompson, et al.
Translational Andrology and Urology|November 16, 2023
<sup>68</sup>Ga-PSMA-PET/CT in addition to mpMRI in men undergoing biopsy during active surveillance for low- to intermediate-risk prostate cancer: study protocol for a prospective cross-sectional studyWilliam Gondoputro, Paul Doan, Athos Katelaris, et al.
BJU International|July 10, 2019
Diagnostic accuracy of <sup>68</sup> Ga-prostate-specific membrane antigen (PSMA) positron-emission tomography (PET) and multiparametric (mp)MRI to detect intermediate-grade intra-prostatic prostate cancer using whole-mount pathology: impact of the addition of <sup>68</sup> Ga-PSMA PET to mpMRIMatthijs J Scheltema, John I Chang, Phillip D Stricker, et al.
World Journal of Urology|March 30, 2018
Pair-matched patient-reported quality of life and early oncological control following focal irreversible electroporation versus robot-assisted radical prostatectomyMatthijs J Scheltema, John I Chang, Maret Böhm, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
The Journal of Urology|August 10, 2022
Final Analysis of the Magnetic Resonance Imaging in Active Surveillance TrialPaul Doan, Matthijs J Scheltema, Amer Amin, et al.
The Journal of Urology|September 12, 2022
Reply by AuthorsPaul Doan, Matthijs J Scheltema, Amer Amin, et al.
BJU International|April 27, 2022
Outcomes of salvage radical prostatectomy after initial irreversible electroporation treatment for recurrent prostate cancerLuigi A M J G van Riel, Bart Geboers, Ertunc Kabaktepe, et al.
BJU International|December 10, 2022
Salvage irreversible electroporation for radio-recurrent prostate cancer - the prospective FIRE trialAlexandar Blazevski, Bart Geboers, Matthijs J Scheltema, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 4, 2022
Robot-Assisted Prostate-Specific Membrane Antigen-Radioguided Surgery in Primary Diagnosed Prostate CancerWilliam Gondoputro, Matthijs J Scheltema, Alexander Blazevski, et al.
The Journal of Urology|December 12, 2019
The Magnetic Resonance Imaging in Active Surveillance (MRIAS) Trial: Use of Baseline Multiparametric Magnetic Resonance Imaging and Saturation Biopsy to Reduce the Frequency of Surveillance Prostate BiopsiesAmer Amin, Matthijs J Scheltema, Ron Shnier, et al.
BJU International|January 21, 2020
Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancerAmer Amin, Alexandar Blazevski, James Thompson, et al.
Translational Andrology and Urology|November 16, 2023
<sup>68</sup>Ga-PSMA-PET/CT in addition to mpMRI in men undergoing biopsy during active surveillance for low- to intermediate-risk prostate cancer: study protocol for a prospective cross-sectional studyWilliam Gondoputro, Paul Doan, Athos Katelaris, et al.
BJU International|July 10, 2019
Diagnostic accuracy of <sup>68</sup> Ga-prostate-specific membrane antigen (PSMA) positron-emission tomography (PET) and multiparametric (mp)MRI to detect intermediate-grade intra-prostatic prostate cancer using whole-mount pathology: impact of the addition of <sup>68</sup> Ga-PSMA PET to mpMRIMatthijs J Scheltema, John I Chang, Phillip D Stricker, et al.
World Journal of Urology|March 30, 2018
Pair-matched patient-reported quality of life and early oncological control following focal irreversible electroporation versus robot-assisted radical prostatectomyMatthijs J Scheltema, John I Chang, Maret Böhm, et al.
Pageof 4